Navigation Links
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Date:8/19/2013

ed merger transaction with Immune Pharmaceuticals; the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for AmiKet™ or crolibulin™ will not be successful; the risk that AmiKet™, Azixa® or crolibulin™ will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all; the risk that Ceplene® will not receive regulatory approval or marketing authorization in the United States or Canada; the risk that Ceplene® will not achieve significant commercial success; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securit
'/>"/>
SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EpiCept Reports Second Quarter 2013 Operating and Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... MINNEAPOLIS, MN , May 1, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has priced ... common stock at a price of $9.00 per share, ... option to purchase up to an additional 585,000 shares ... Company will be $35.1 million.  The offering is expected to ...
(Date:5/1/2015)... May 1, 2015 A new ... antithrombotic drugs will reach $22.4bn in 2019. That revenue ... Industry and Market Prospects 2015-2025 ,  published ... investigation is to provide forecasts and qualitative analyses of ... publisher and consultancy in London, UK ...
(Date:5/1/2015)... , May 1, 2015 ... Production Market by Product (Equipment, Consumables), by Type (Monoclonal, ... Diagnostic Labs, Research Institutes) - Analysis & Global ... studies the global Antibody Production Market for the ... is expected to reach $2.572 Billion by 2019 ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... Highlights Include Clinical Trial Updates, BETHESDA, Md., ... NWBT; OTC Bulletin Board: NWBO), (the,"Company or NWBT"), ... and Chief Executive Officer, will deliver a presentation ... vaccines for the,treatment of cancer, at the "Next ...
... (July 17, 2008) Researchers at the U.S. Department of ... have won two R&D 100 Awards for innovative fluid ... been awarded 101 R&D 100 Awards since the awards ... R&D 100 Award -- dubbed the "Oscars of innovation" ...
... Opens at The O2 This Autumn, - With ... exhibition to premiere at The O2, Body,Worlds & The ... von Hagens, go on sale today., (Photo: ... In partnership with the producers of the sensation ...
Cached Biology Technology:Northwest Biotherapeutics to Present at Next Generation Vaccine Conference 2Argonne researchers win 2 R&D 100 Awards 2Argonne researchers win 2 R&D 100 Awards 3Argonne researchers win 2 R&D 100 Awards 4Tickets for Brand New Exhibition 'Body Worlds & The Mirror of Time' on Sale 18 July 2Tickets for Brand New Exhibition 'Body Worlds & The Mirror of Time' on Sale 18 July 3
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... exists that people who lived or worked at Camp ... and 1985 were exposed to the industrial solvents tricholorethylene ... strong scientific evidence is not available to determine whether ... contaminants, says a new report from the National Research ...
... researchers have accelerated research into Multiple Sclerosis by discovering ... unravel the causes of MS and other autoimmune disease. ... in the prestigious journal Nature Genetics . ... mystery. This discovery reveals important new insights into the ...
... protein known to be overly active in breast cancer ... the structural composition of mammary tissue, potentially making it ... Lombardi Comprehensive Cancer Center at Georgetown University Medical Center ... in Washington, DC, the scientists report that the protein, ...
Cached Biology News:Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study 2Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study 3Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study 4Aussie and Kiwi researchers make double MS genetic discovery 2Protein linked to change in tissue that surround and support breast tumors 2
... adapter allows the Thermo-Fast® ... AB-1000) PCR plates to ... ABI PRISM® 3700 capillary ... for information on the ...
... • Heat activated ,• Eliminates ... temperature ,• Excellent specificity allows extension ... secondary structures ,• Leaves an 'A' ... modified form of GeneChoice DNA Polymerase ...
... Form: buffered aqueous solution. ... from complex carbohydrates and glycoproteins. It is ... conditions where the pH must be neutral ... Unit Definition: One ...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: